Design Qualification SOP
|
|
- Aubrey Ball
- 6 years ago
- Views:
Transcription
1 1.0 Commercial in Confidence 16-Aug of 13 Design Qualification SOP Document No: SOP_0400 Prepared by: David Brown Date: 16-Aug-2006 Version: 1.0
2 1.0 Commercial in Confidence 16-Aug of 13 Document Approval Name Role Date Signature David Brown Author Document Control Version Author Date Description 1.0 David Brown 16-Aug-2006 First version.
3 1.0 Commercial in Confidence 16-Aug of 13 Table of Contents 1 Introduction Purpose Scope Definitions Responsibility References Design Qualification Process Business Requirements Review Functional Design Review Technical Design Source Code Control Coding Standards Code Reviews Unit (Component) Testing Validation Change Control Process Design Qualification - Phase Entry/Exit Phase Entry Phase Exit Design Qualification Protocol - Preparation Protocol Title Pre-approval Introduction Regulatory Requirements Methodologies Documents to be reviewed Acceptance Criteria Design Qualification Report Report on the design evaluation process Summary and Conclusions Protocol Results Acceptance... 12
4 1.0 Commercial in Confidence 16-Aug of 13 1 Introduction 1.1 Purpose 1.2 Scope The Design Qualification process ensures that a computer system requiring validation to is designed to meet the regulatory requirements of the pharmaceuticals industry. Department/Section: Client, IT and Validation groups. This SOP will apply to the design of all computer systems that require validation to meet pharmaceutical industry regulatory requirements. For information on computer systems that require validation see SOP SOP_0200 Validation Determination. 1.3 Definitions Project Team the team formed by the business to implement a new computer system. This team will typical comprise of: a project manager, users, software engineers, IT support staff, trainers, and IT quality assurance staff. Client the business system owner is typically the line manager responsible for the business process where the computer system will be used. Validation Group the group responsible for ensuring that computer systems are implemented and maintained in a validated state. IT Group the group responsible for development, operation, and maintenance of computer systems. 1.4 Responsibility The overall responsibility to ensure that the DQ is carried out in accordance with this SOP lies with the Business System Owner. The Project Team are responsible for ensuring that they follow the process described in this document is followed. The Validation group is responsible for the production of the Design Qualification Protocol document and Design Qualification Report.
5 Title Design Qualification SOP 1.0 Commercial in Confidence 16-Aug of References Document ID SOP_0102 SOP_0401 SOP_0402 SOP_0900 Title Document Standards Code Review SOP Unit Testing SOP Validation Change Control SOP
6 1.0 Commercial in Confidence 16-Aug of 13 2 Design Qualification Process 2.1 Business Requirements Review The User requirements must be documented either as a conceptual description of the system or as a formal statement of user requirements prior to the start of the validation process. The User requirements specification must be reviewed to ensure that the appropriate regulatory conformance requirements are present. These requirements relate to: US Food and Drug Administration 21 CFR Part 211 Current Good Manufacturing Practice For Finished Pharmaceuticals US Food and Drug Administration 21 CFR Part 11 Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application International Committee for Harmonization (ICH) Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance International Committee for Harmonization (ICH) Electronic Standards for the Transfer of Regulatory Information (ESTRI) International Committee for Harmonization (ICH) Electronic Common Technical Document Specification US Food and Drug Administration Guidance for Industry: Computerized Systems Used In Clinical Trials US Food and Drug Administration 21 CFR Part 58 Good Laboratory Practice For Nonclinical Laboratory Studies All Requirements should have a unique identifier to allow for traceability of system functionality back to requirements. 2.2 Functional Design Review The functional design must be reviewed to ensure the business requirements, specifically the regulatory requirements, are addressed in the Functional Requirements Specification. The compliance related functions are: The use of electronic signatures; Access control mechanisms; Audit trails;
7 1.0 Commercial in Confidence 16-Aug of 13 Backup and recovery; Resilience and data integrity, and; Disaster recovery. 2.3 Technical Design Ensure that the technical design specification provides a concise definition of each software module. These definitions must be traceable back to business functions expressed in the Functional Requirements Specification. 2.4 Source Code Control Ensure that all source code related to a validated system is stored in a validated source code control system unless manual procedures are in place to ensure the version management of source code during development. 2.5 Coding Standards Coding standards are vital to ensure consistency and supportability of a computer system. As part of the DQ process it is the responsibility of the project team to ensure that coding standards are employed. 2.6 Code Reviews Evidence must be present that source code reviews have been conducted as part of the development process. (See SOP_401 Code Review SOP). 2.7 Unit (Component) Testing The final step of the design phase of the system should be unit testing. Unit testing should ensure that the components meet the standards identified in the SDLC used. (See SOP_402 Unit Testing SOP). 2.8 Validation Change Control Process The change control process begins at the point of approval of the user requirements specification. This is important to ensure that traceability of requirements is maintained. (See SOP_0900 Validation Change Control SOP).
8 1.0 Commercial in Confidence 16-Aug of 13 3 Design Qualification - Phase Entry/Exit 3.1 Phase Entry The entry point for the Design Qualification is the approval of the User Requirements Specification or concept statement. 3.2 Phase Exit The exit point for the Design Qualification phase of validation is the approval of the Design Qualification Report.
9 1.0 Commercial in Confidence 16-Aug of 13 4 Design Qualification Protocol - Preparation The Design Qualification Protocol describes the process to be followed that will ensure the design and development of a computer system does not compromise its validated status. The audience for the DQ protocol will be business staff within the company and industry regulators. Therefore, the document wherever possible should be written in non-professional terms. The DQ document must be able to be read in isolation and therefore provide enough detail on the purpose of the system. The Design Qualification Protocol must be created to conform to the SOP_102 Documentation Standards SOP. The following subsections provide a synopsis of the content of the DQ protocol. 4.1 Protocol Title Give the Protocol a descriptive title, which reflects the scope of testing performed in the Protocol and provides sufficient differentiation between this Protocol and other protocols for the system. 4.2 Pre-approval At the beginning of the DQ Protocol a pre-approval section is required. This section will contain a table for signatures. The table of signatures must provide for the following information to be captured: 1. The department or function of the signatory; 2. The name of the signatory; 3. A space to record the signature, and; 4. A space to record the date of the signature. The section must contain a statement informing the reviewer that signing this document infers that they have read, understood and agree with the contents of the protocol. Normally this information is collected on the approval page of the DQ Protocol.
10 1.0 Commercial in Confidence 16-Aug of Introduction The introduction section of the DQ protocol must contain subsections providing information on: 1. The objectives of the DQ protocol; 2. The scope of the DQ protocol stating the phase of the implementation lifecycle the IQ protocol applies too; 3. A list of documents referenced in the DQ protocol; 4. A description of the system being designed which identifies the intended use of the system. 4.4 Regulatory Requirements Details of the international regulatory requirements that apply to the computer system being validated must be identified. 4.5 Methodologies This section of the DQ protocol must identify any Software Development Lifecycle or development methodology to be used in the design and development of the system. This section must describe any issues identified with this methodology and the controls that have been put in place to address these issues. 4.6 Documents to be reviewed This section must identify the document to be reviewed as part of the DQ process. In addition, this section must identify any documents that have been omitted or are to be omitted with an explanation of the reasons for their omission. 4.7 Acceptance Criteria List the criteria the system must meet to satisfy the objectives of the DQ. Acceptance Criteria must meet the following standards: The Acceptance Criteria (AC) must be unambiguous, measurable, and verifiable. Terms such as appropriate and very are not acceptable in most functions. Examples: o Unacceptable AC: The Technical Design Specification will contain appropriate definitions of code modules.
11 1.0 Commercial in Confidence 16-Aug of 13 o o Acceptable AC: The Technical Design Specification will contain detailed definitions of code modules including... Unacceptable AC: A message will display when an invalid quantity is entered. o Acceptable AC: A message will display indicating entry of an invalid quantity. Number or uniquely label the Acceptance Criteria so they may later be identified. The Acceptance Criteria should have their basis in the user requirement specification and relevant regulatory requirements.
12 1.0 Commercial in Confidence 16-Aug of 13 5 Design Qualification Report On completion of the Design Qualification process the Design Qualification protocol is revised to include the following sections: Report on the design evaluation process; Summary and Conclusions, and; Protocol Results Acceptance. The inclusion of these sections in the DQ protocol and the associated approval process of the revised DQ protocol will create the Design Qualification Report (DQR). 5.1 Report on the design evaluation process This section identifies: The results of the evaluation of the identified design documents against the user requirements, regulatory requirements, and SDLC/QA processes; Details of the change generated during the design qualification process. See SOP_0900 Validation Change Control SOP. 5.2 Summary and Conclusions Provide a summary of the results of the design qualification process and any encountered deviations. Problems encountered during execution of protocols will be summarised according to: protocol errors, execution errors, specification errors, and non-conformance to regulatory requirements and requirements expressed in the user requirements specification. 5.3 Protocol Results Acceptance The last section of the DQ report must be the Protocol Results Acceptance section. This section records the approval of the revised DQ protocol that forms the DQR. This section will contain a table for signatures. The table of signatures must provide for the following information to be captured: 1. The department or function of the signatory; 2. The name of the signatory; 3. A space to record the signature, and; 4. A space to record the date of the signature.
13 1.0 Commercial in Confidence 16-Aug of 13 The section must contain a statement informing the reviewer that signing this document infers that they have read, understood and agree with the contents of the protocol.
Validation Planning SOP
1.0 Commercial in Confidence 03-Aug-2006 1 of 10 Validation Planning SOP Document No: SOP_0300 Prepared by: David Brown Date: 03-Aug-2006 Version: 1.0 1.0 Commercial in Confidence 03-Aug-2006 2 of 10 Document
More informationImplementation Life-cycle SOP
1.0 Commercial in Confidence 11-Aug-2006 1 of 12 Implementation Life-cycle SOP Document No: H4_SOP_0100 Prepared by: David Brown Date: 11-Aug-2006 Version: 1.0 1.0 Commercial in Confidence 11-Aug-2006
More informationGAMP5 Validation for Dynamics 365
GAMP5 Validation for Dynamics 365 Prepared by: Michael Webster, Business Development Director, RSM US LLP michael.webster@rsmus.com, +1 617 241 1544 Dynamics 365 is an ideal enterprise resource planning
More informationManaging Validation. Paperless Recorders
Managing Validation Paperless Recorders Multitrend Plus Validation Background The past five years has seen an increase in the use of computerized systems and products in the pharmaceutical and bio-pharmaceutical
More informationAutomated System Validation By: Daniel P. Olivier & Curtis M. Egan
Automated System Validation By: Daniel P. Olivier & Curtis M. Egan In today s technical environment validation practices are both a requirement and an important tool in the medical and pharmaceutical industry.
More informationWorld Journal of Pharmaceutical Research SJIF Impact Factor 5.990
SJIF Impact Factor 5.990 Volume 4, Issue 9, 444-454. Review Article ISSN 2277 7105 COMPUTER SYSTEM VALIDATION: A REVIEW Patil Yogesh* Mali Kamlesh, Bodhane Mohini, Ram Phad, Shaikh Ismail, Lale Shivam
More informationCSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017
CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationBeamex CMX Calibration Software and GAMP - Good Automated Manufacturing Practices
Beamex CMX Calibration Software and GAMP - Good Automated Manufacturing Practices GAMP Good Automated Manufacturing Practices The GAMP Forum was established in 1991 to help promote the understanding of
More informationThe Role of the LMS in 21 CFR Part 11 Compliance
The Role of the LMS in 21 CFR Part 11 Compliance Co-author: Dr. Bob McDowall, Director R.D. McDowall Limited ABSTRACT The purpose of this white paper is to describe how NetDimensions Learning addresses
More informationGAMP Guideline & Validation Documentation
GAMP Guideline & Validation Documentation Danilo Maruccia Milano, 21 Marzo 2006 GAMP Guideline & Validation Documentation GAMP Guideline Planning documents Specification Documents Testing Documents Acceptance
More informationCOMPUTERIZED SYSTEM VALIDATION (CSV) IMPLEMENTATION, DEMARCATION AND STRUCTURATION
COMPUTERIZED SYSTEM VALIDATION (CSV) IMPLEMENTATION, DEMARCATION AND STRUCTURATION Audit Security is the high priority for pharmaceutical companies, especially when computerized Systems are used. The everchanging
More informationRegulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)
Regulatory Overview Annex 11 and Part 11 Sion Wyn Conformity +[44] (0) 1492 642622 sion.wyn@conform-it.com 1 Two Key Regulations Annex 11 21 CFR Part 11 Apply to the regulated company, but often have a
More informationComputer System Validation Perform a Gap Analysis of your CSV Processes
Computer System Validation Perform a Gap Analysis of your CSV Processes Chris Wubbolt, QACV Consulting Computer and Software Validation Conference April 27, 2017 www.qacvconsulting.com 1 Objectives Computer
More informationImplement Effective Computer System Validation. Noelia Ortiz, MME, CSSGB, CQA
Implement Effective Computer System Validation Noelia Ortiz, MME, CSSGB, CQA Session Outline 1 2 3 4 5 Understanding Regulations and Guidelines Pertaining to Computer Systems Integrate SDLC and GAMP 5
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationUnderstanding GxP Regulations for Healthcare
Understanding GxP Regulations for Healthcare GxP Guidelines What is GxP? GxP is a collection of quality guidelines and regulations created to ensure that bio/pharmaceutical products are safe, meet their
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationJune Are You Prepared for Validation?
June 2010 Are You Prepared for Validation? Are you prepared for validation? For industries that operate in regulated environments, validation of processes and systems is an important and required part
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationThe SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies
The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies By Rob Sims, UL Compliance to Performance When Life Sciences companies
More informationDFUG 2015 Audit Report
presents DFUG 2015 Audit Report Michael Holdsworth Phil Kirsch Overview The DataFax User Group (DFUG) vendor audit is a combined user group audit that allows DataFax users to determine whether DF/Net Research
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationSven Trelle CTU Bern University of Bern
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6(R2) Integrated Addendum to Good Clinical Practice (GCP) Guideline Sven Trelle CTU Bern University
More informationDATA INTEGRITY RISK ASSESSMENT
DATA INTEGRITY RISK ASSESSMENT 1 1 Main DI risks 2 Main DI failures Access to data systems are not matched by role or function to job description For example, The Owner who is the COO of the company has
More informationGxP Compliance for Computerized Systems
GxP Compliance for Computerized Systems The Second Annual Pharmaceutical Industry Regulatory and Compliance Summit David L. Stone General Manager, Validation Services Glemser Technologies June 13, 2001
More informationA Comprehensive Approach to Find and Remediate Data Integrity Problems
A Comprehensive Approach to Find and Remediate Data Integrity Problems June 14, 2017 Copyright 2017 QuintilesIMS. All rights reserved. What is data integrity? Whom does it apply to? Definitions matter
More informationLatino America Consultores Innovation & Technology to make your Business Compliant
Latino America Consultores Innovation & Technology to make your Business Compliant Annex 15 & EMA Process Validation Guide Line 1 Changes in Requirements The Pharmaceutical Industry has adapted its business
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More information[ WHITE PAPER ] A Basic Overview: Meeting the PIC/S Requirements for a Computerized System INTRODUCTION GOOD MANUFACTURING PRACTICES
A Basic Overview: Meeting the PIC/S Requirements for a Computerized System Lynn Archambault Waters Corporation, Milford, MA, USA INTRODUCTION The Pharmaceutical Inspection Convention and Pharmaceutical
More informationPreparing for a Software Quality Audit
Preparing for a Software Quality Audit By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Preparing for a Software
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationDevelop a Roadmap for the Implementation of a Global CSV Program. Eileen Cortes April 26, 2017
Develop a Roadmap for the Implementation of a Global CSV Program Eileen Cortes April 26, 2017 Agenda CSV Regulation Principles CSV Lifecycle Approach CSV and Quality Management Governance Program and CSV
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationRisk-Based Approach to SAS Program Validation
Paper FC04 Risk-Based Approach to SAS Program Validation Keith C. Benze SEC Associates, Inc. 3900 Paramount Parkway, Suite 150 South Morrisville, NC 27560 ABSTRACT SAS is widely used throughout the FDA
More informationReport. Quality Assessment of Internal Audit at <Organisation> Draft Report / Final Report
Report Quality Assessment of Internal Audit at Draft Report / Final Report Quality Self-Assessment by Independent Validation by Table of Contents 1.
More informationGood Distribution Practices Toolkit Change Control 10 March 2016
Good Distribution Practices Toolkit Change Control 10 March 2016 1 Disclaimer The content of this presentation were derived mainly from WHO training material on Change Control and edited to suit the Distributor
More informationICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄
ICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄 Mandy Liu 劉文婷 COQM/ Boehringer Ingelheim Taiwan Ltd Former Team leader GCP inspection team/ CDE Member of Expert Working Group of ICH E6 2016.11.23 Statement of the
More informationEU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationStandard Operating Procedures
Auditing of a Technology Vendor Checklist This checklist is intended to be a guide to planning your next audit. The items here should be evaluated for completeness. It is crucial for both Quality and the
More informationAddressing the Paradigm Shift in Regulatory Inspections
An Executive Summary Addressing the Paradigm Shift in Regulatory Inspections Understanding the paradigm shift in a regulatory audit and what it means from an electronic system perspective. Humera Khaja
More informationRisk-based Approach to Part 11 and GxP Compliance
Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!
More informationStandard operating procedures (SOPs) are
Standard Operating Procedures in Clinical Research: A Beginner s Guide Michael R. Hamrell a, * and Bruce Wagman b a MORIAH Consultants, Yorba Linda, CA, USA b MDS Pharma Incorporated, Sentry Parkway, WestBlue
More informationVALIDATION READY IT PROJECTS OF BEAS INDUSTRY SOLUTIONS BASED ON SAP BUSINESS ONE
White Paper VALIDATION READY IT PROJECTS OF BEAS INDUSTRY SOLUTIONS BASED ON SAP BUSINESS ONE The comprehensive Solution for small and mid-sized Manufacturing Enterprises in regulated Industries CONTENT
More informationManual 069 The validation of facilities and system
1. Purpose The purpose of this guideline is to provide requirements for the Validation of Facilities and Systems and to outline recommendations on how to achieve compliance. 2. Scope This guideline can
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationValidation Strategies for Equipment from Multiple Vendors
Welcome to our E-Seminar: Validation Strategies for Equipment from Multiple Vendors Page 1 Content FDA guidelines and inspectional observations Validation & Qualification Approaches Instrument Qualification
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationGeneral Requirements for the Competence of Testing and Calibration Laboratories
ISO 17025:2005 POSITION PAPER General Requirements for the Competence of Testing and Calibration Laboratories EXECUTIVE SUMMARY This position paper provides a high-level overview of how LabVantage supports
More informationISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua
ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND
More informationSystem Requirements (URS)
System s (URS) System Document Control System Document ID URS000XXX Version 1 DOCUMENT APPROVALS Reason For Signature Name Position Signature Date Prepared by Vic Johnson Project Manager Checked for accuracy
More informationAuditing Software Vendors
Auditing Software Vendors By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Auditing Software Vendors Copyright
More informationSummary of Significant Changes. Policy
This Policy replaces POL251/1 Copy Number Effective 03/04/17 Summary of Significant Changes Addition of requirements of 2016 review of Guidance by MHRA, ALCOA+, and documents related to Policy The purpose
More informationBasic Good Laboratory Practice. Christopher Jerome, B.Vet.Med., Ph.D
Basic Good Laboratory Practice Christopher Jerome, B.Vet.Med., Ph.D Goals Outline the concept of Good Laboratory Practice (GLP) Provide some specific guidelines applicable to day to day work in the laboratory
More informationValidation and Automated Validation
TOP INDUSTRY QUESTIONS Validation and Automated Validation 1 Table of Contents 03 04 07 10 13 16 19 INTRODUCTION SECTION 1 - Validation Standards How is validation defined under Title 21 CFR Part 11? What
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationReferences Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.
References Concept Principle a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which
More informationChapter 2 GALP Implementation Assistance
Chapter 2 GALP The GALP Implementation is based on established data management principles. 1. PRINCIPLES Control is the essential objective behind most data management principles. Effective management
More informationContents. Contents (13) 1 Qualification (21)
1 Qualification (21) 1.A Official requirements (23) 1.A.1 Legal aspects of qualification (23) 1.A.2 Documentation of the qualification (26) 1.A.3 Design Qualification (DQ) (27) 1.A.4 Installation Qualification
More informationDATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS
GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017 DATA INTEGRITY & CSV:
More informationChapter 1. Pharmaceutical Industry Overview
Chapter 1 Pharmaceutical Industry Overview 1.1 Introduction 2 1.2 Regulations 2 1.2.1 Health Insurance Portability and Accountability Act 2 1.2.2 The Code of Federal Regulations 3 1.2.3 Guidance for Industry
More informationJean Guichard. Introduction to Good Process Record Management (GxP) #: Internet-WP Version: e1.00 /EN
Jean Guichard White Paper Introduction to Good Process Record Management (GxP) #: Internet-WP Version: e1.00 /EN Introduction to Good Process Record Management (GxP) 2 / 6 Document History Version Date
More informationZOLL Document Number: 90E0004 Page 5 of 15 Maintenance of Quality Records
ZOLL Number: 90E0004 Page 5 of 15 1. INTRODUCTION 1.1 Purpose 1.2 Scope The purpose of this document is to provide guidance regarding the identification of a quality record and the documentation practices
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationQuality Manual. Index
This quality policy manual is for the use of, its Clients, Vendors, and the appropriate Regulatory Agencies. Unauthorized duplication or transfer to others is prohibited. Index Authorization... 3 Introduction...
More informationTesting 2. Testing: Agenda. for Systems Validation. Testing for Systems Validation CONCEPT HEIDELBERG
CONCEPT HEIDELBERG GMP Compliance for January 16-17, 2003 at Istanbul, Turkey Testing for Systems Validation Dr.-Ing. Guenter Generlich guenter@generlich.de Testing 1 Testing: Agenda Techniques Principles
More informationGuidance for Industry - Computerized Systems Used in Clinical Trials
Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials
More informationIncorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance
Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The
More informationLife Sciences Courseware. Knowledge. Performance. Impact.
Life Sciences Courseware Knowledge. Performance. Impact. Now there s a flexible, affordable way to achieve your compliance training goals. In the Life Sciences industry, it s vital that your people are
More informationProject Procedure 1.0 PURPOSE 2.0 SCOPE 3.0 REFERENCES 4.0 DEFINITIONS. No.: P /21/2012 PAGE 1 OF 8 INTERNAL QUALITY AUDITS
Project Procedure INTERNAL QUALITY AUDITS 09/21/2012 PAGE 1 OF 8 1.0 PURPOSE The purpose of this procedure is to establish the requirements for a comprehensive system of planned and documented internal
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations National Genetics Institute 17-Jan-06 Department of Health and Human Services Public Health Service Food and Drug Administration Los Angeles
More information10 "Must-Haves" for the Life Sciences Learning Management System
10 "Must-Haves" for the Life Sciences Learning Management System Why the Life Sciences LMS Needs to Demonstrate Record Control UL talks to many Life Sciences companies that are exploring learning and development
More informationGMP Compliance. George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd
GMP Compliance George Acevedo, CQV Senior Engineer M+W Singapore Pte. Ltd June 2017 Overview GMP Definition and Regulation Our Philosophy and Strategy for Compliance Project Lifecycle Deliverables Master
More informationInspection-Ready IRT. Valarie Higgins President & Managing Director Almac Clinical Technologies.
Inspection-Ready IRT Valarie Higgins President & Managing Director Almac Clinical Technologies www.almacgroup.com 2 Biologics License Application and the IRT Provider IRT 3 Agenda Why is IRT Becoming an
More informationQuality Risk Management
Quality Risk Management Audit Expectations and Observations Matthew Davis Lead Auditor Office of Manufacturing Quality, TGA CAPSIG 4 th May 2011 www.tga.gov.au 2 QRM - TGA Expectations and Observations
More informationValidation Strategies for Equipment from Multiple Vendors
David Heiger, Ph.D. Worldwide Compliance & NDS Services Manager 10. December 2002 Validation Strategies for Equipment from Multiple Vendors Time: 3.00 pm Central European Time Telephone Number: +44 20
More informationProcess ERP, an ideal software solution for Life Science industries
Process ERP, an ideal software solution for Life Science industries Update on FDA's current compliance requirements of GxP regulated computerized systems Ravi Jotwani, Ph.D University of Louisville ProcessManufacturingSoftware
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationEU Annex 11 US FDA , (g), (i), 11 Orlando López 09-APR
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationGeneral European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (08) 69 R7 VALIDATION OF COMPUTERISED SYSTEMS CORE DOCUMENT Full document title and reference Document type Validation of Computerised
More informationEnsure Data Integrity Compliance Enterprise-Wide
Ensure Data Integrity Compliance Enterprise-Wide PharmaQual 360 º Conference February 24, 2017 Chris Wubbolt QACV Consulting, LLC www.qacvconsulting.com 1 Objectives What is data integrity and the definition
More informationWorld Journal of Pharmaceutical Research SJIF Impact Factor 5.990
SJIF Impact Factor 5.990 Volume 5, Issue 01, 1092-1134. Research Article ISSN 2277 7105 COMPUTER VALIDATION AND ETHICAL SECURITY MEASURES FOR PHARMACEUTICAL DATA PROCESSING Omprakash G. Bhusnure 1*, Kendre
More informationStephanie Gentilin, CCRA
Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring
More informationSingapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum
Singapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum 25 August 2017 TOPIC: Issue Management / Quality Risk Management Implications with ICH GCP E6 (R2) and
More informationTop Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp
Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp 2016 Regulatory Compliance Associates Inc. Top Observation for 5 years Year Drugs #1 citation Device #1 citation
More informationComputer. Systems Validation. Full Time Part Time Online.
Computer Systems Validation Full Time Part Time Online www.dpseng.com.sg Contents 1. Welcome 2. Programme Overview 3. Programme Content www.dpseng.com.sg 2 Welcome Transition into a new career in the Pharmaceutical
More informationMDSAP Purchasing Process
MDSAP Purchasing Process The Medical Device Single Audit Program, MDSAP, evaluates companies on their compliance to requirements based on ISO 13485:2016 and national regulations. An MDSAP audit looks at
More informationFacilitating Compliance with 21 CFR Part 11
Facilitating Compliance with 21 CFR Part 11 Michael Hurley Director of Product Management at Complion Disclosure MICHAEL HURLEY Director, Product Management Complion, Inc. I have no relevant financial
More informationUNIFI 1.5 : Simplifying Qualification and Validation June 2012
UNIFI 1.5 : Simplifying Qualification and Validation June 2012 2011 Waters Corporation 1 Waters Regulated Bioanalysis System Solution Sample Preparation Solutions Best in class ACQUITY UPLC I-Class The
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationCONSIDERATIONS OF CONTINUOUS MANUFACTURING PROCESSES
LCDR Patric Klotzbuecher U.S. FDA/Office of Regulatory Affairs/New York District 3 rd FDA/PQRI Conference on Advancing Product Quality March 22 24, 2017 CGMP AND REGULATORY CONSIDERATIONS OF CONTINUOUS
More informationValidation of Pharmaceutical Manufacturing Process Focus: APIs.
Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised
More informationInspection Trends. American Society for Quality Richmond, VA Section March 8, 2016
Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality
More informationRegulatory Expectations, Standards & Guidelines
Regulatory Expectations, Standards & Guidelines Regulatory Requirements Pharmacopeias Good Automated Manufacturing Practice (GAMP) 21 CFR Part 11 and Annex 11 Consequences of Non-Compliance 22 Regulatory
More informationISO 9001:2015 Gap Analysis Check Sheet
CONTEXT OF THE ORGANIZATION 4.1 Understanding the organization and its context Organization shall determine external and internal issues that are relevant to its purpose and strategic direction and that
More information